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Liposomes equipped with cellular uptake-mediating peptidic vector compounds have attracted much attention as target-specific drug delivery
systems. Aside from the development of the target recognition motif itself, vector coupling to liposomes while conserving the active conformation
constitutes an important element in carrier development. To elucidate the most efficient way for adsorptive peptide binding to liposomes, we
synthesized and characterized two-domain peptides comprising a cationic sequence derived from the binding domain of apolipoprotein E (apoE)
for the low-density lipoprotein receptor and different lipid-binding motifs, that is, an amphipathic helix, a transmembrane helix, single fatty acids
or two palmitoyl chains. Peptide properties considered relevant for peptide–liposome complexes to initiate an endocytotic cellular uptake such as
lipid binding, helicity, stability of anchorage, bilayer-disturbing activity, and toxicity showed that the dipalmitoyl derivative was the most suitable
to associate the apoE peptide to the surface of liposomes. The peptide showed pronounced lipid affinity and was stably anchored within the lipid
bilayer on a time scale of at least 30 min. The helicity of about 40% in the lipid-bound state and the location of the amphipathic helix on the
liposomal surface provided the prerequisites for interaction of the complex with the cell surface-located receptor. The concentration of the
dipalmitoylated peptide to permeabilize neutral lipid bilayers (lipid concentration 25 μM) was 0.06 μM and a 2 μM concentration reduced cell
viability to about 80%. Efficient internalization of liposomes bearing about 180 peptide derivatives on the surface into brain capillary endothe-
lial cells was monitored by confocal laser scanning microscopy. The concept of complexation using dipalmitoylated peptides may offer an
efficient substitute to covalent vector coupling and a prospective way to optimize the capacity of liposomes as drug delivery systems also for
different targets.
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Liposomes are advantageous carriers for many drugs as they
can be loaded with hydrophobic as well as hydrophilic com-
pounds to overcome unfavorable properties such as poor solu-
bility, low stability, rapid metabolization and toxicity [1,2].
However, in many cases, a lack of specificity still limits the
potential advantages of liposomal drug administration. One ap-
proach to tackle this problem is carrier derivatization with a
ligand that recognizes membrane constituents [3] and mediates
drug transport across barriers such as the blood–brain barrier
(BBB) [4].
The accessibility of drugs to the central nervous system is
highly limited by the blood–brain barrier. The continuous layer of
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cellular permeation [5]. A promising strategy to overcome this
barrier is the activation of transcytotic transport routes [6]. So far,
evidence for vector-mediated drug delivery to the brain is most
convincing for immunoliposomes equipped with monoclonal
antibodies against the transferrin receptor [7,8].
The BBB is also rich in the low-density lipoprotein receptor
(LDLr) [9]. Its role in the transcytotic uptake of cholesterol-rich
lipoproteins into the brain has been demonstrated [10]. One
ligand for LDLr is apolipoprotein E (apoE), a 299-amino acid
residue, two-domain protein [11] consisting of a large globular
part, which contains the LDLr recognition site in the sequence
136–150, and a lipid-binding region for anchorage within the
lipoprotein. Lipoprotein-like particles prepared by complexing
apoE with liposomes are successfully used for tumor-specific
drug application [12–15]. Drugs that have been efficiently trans-
ported across the BBB using apoE-coated nanoparticles include
the analgetic hexapeptide dalargine and the tumor therapeutic
doxorubicin [16,17].
Although the entire apoprotein can be applied for carrier
modification, truncated sequences containing only the residues
required for receptor binding might be used advantageously.
Thus, synthetic peptides such as the tandem dimer (141–150)2
were found to compete with LDL for receptor binding [18] and
to induce endocytosis in cultivated cortical neurons [19]. How-
ever, when the peptide is covalently bound to the polar surface of
polyethyleneglycol-coated liposomes, uptake of the complex
into cells is determined by an LDLr-independent mode [20].
Most likely, the peptide located in the rather polar environment is
not able to assume the helical structure that has been suggested to
be a prerequisite for receptor recognition [18]. In contrast, pep-
tides encompassing the whole or larger parts of the receptor-
binding region of apoE (136–150) and modified with one or two
fatty acid chains [21] as well as an apoE peptide linked to a class-
A amphipathic peptide [22,23] associate with LDL and likely
involve the LDL receptor in the cellular uptake process.
Thus, in addition to the development of the target recognition
moiety, the optimization of strategies for its coupling to the
carrier is another important element in the development of drug
delivery systems. One approach to coat liposomes with apo E-
derived peptides and to induce the LDLr-competent structure
relies on adsorptive binding to the liposomal surface. We pre-
pared two-domain peptides by modifying the tandem dimer
(141–150)2 with C-terminally coupled amphipathic or highly
hydrophobic helices known to assume an in-plain orientation at
the lipid bilayer [24] or acting as transmembrane building blocks
of manymembrane proteins [25], respectively. Furthermore, one
or two acyl chains, which serve to promote membrane anchorage
and function of several proteins [26,27], were coupled to the N-
terminus of the vector sequence. In this study, we investigated
how the different lipid-associating domains affect lipid binding,
structure, stability of anchorage, bilayer-disturbing activity and
toxicity of the apoE peptide. The main aim was to determine the
peptide derivative which is anchored at the surface of the
liposome in a receptor-accessible way without deterioration of
the vesicle structure on a physiologically relevant time scale. A
combined approach of applying different physical methods suchas fluorescence spectroscopy, circular dichroism (CD) spectros-
copy, isothermal titration calorimetry (ITC) and a toxicity assay
indicates that complexes of the dipalmitoylated apoE derivative
with liposomes seem to be the most promising delivery system
combining the purposes of a stable drug container and of targeting
the blood–brain barrier. Confocal laser scanning microscopic
studies revealed the efficient internalization of the peptide–
liposome complexes into brain capillary endothelial cells.2. Materials and methods
2.1. Materials
Protected amino acids were purchased from Novabiochem (Bad Soden,
Germany). Palmitic acid, myristic acid and other chemicals and solvents used for
peptide synthesis were from Fluka (Buchs, Switzerland). The lipids 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (Rh-DPPE), 1-
palmitoyl-2-stearoyl-(5-DOXYL)-sn-glycero-3-phosphocholine (5-DOX), 1,
2-dioleoyl-sn-glycero-3-phospho(TEMPO)choline (TEMPO), and 1-palmitoyl-
2-stearoyl(6-7)dibromo-sn-glycero-3-phosphocholine (DiBr-PSPC) were pur-
chased from Avanti Polar Lipids (Alabaster, USA). Calcein was obtained from
Fluka (Neu-Ulm, Germany) Tris(hydroxymethyl)aminomethane (Tris), trifluor-
oethanol (TFE), and other chemicals used for biophysical experiments were from
Merck (Darmstadt, Germany). The tissue culture media Alpha-medium/Ham's
F-10 (1/1 v/v), Earle's minimal essential medium, fetal bovine serum, penicillin/
streptomycin, and L-glutamine were from Biochrom (Berlin, Germany), and
fibroblast growth factor and rat tail collagen were from Roche Diagnostics
(Mannheim, Germany). (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl)tetrazolium
bromide (MTT) was obtained from Sigma (Deisenhofen, Germany).
2.2. Peptide synthesis and characterization
The peptides were synthesized on solid phase (TentaGel-S-RAM; Rapp
Polymere, Tübingen, Germany) using an ABI 433A automatic peptide
synthesizer (Applied Biosystems, Foster City, USA) following the standard
Fmoc (9-fluorenylmethoxycarbonyl) chemistry protocol [28]. The peptides were
C-terminally amidated. N-terminal acylation was performed either with acetic
acid or, in the case of P2A2, PA2 and MA2, with palmitic and myristic acid,
respectively. Acylation was performed with diisopropylcarbodiimide and N-
hydroxybenzotriazole overnight. The dipalmitoylated peptide P2A2 was
synthesized using a Dde-protected Fmoc-lysine derivative (Nα-(9-fluorenyl-
methoxycarbonyl)-Nε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-ly-
sine). After coupling of the final tryptophan, the Dde and the N-terminal Fmoc
groups were cleaved off with 2% hydrazine in dimethyl formamide for 10 min.
The two amino groups of the resin-bound peptide (∼50 μmol) were acylated
overnight with a 10-fold excess of palmitic acid activated with diisopropylcar-
bodiimide/N-hydroxybenzotriazole. Cleavage from the resin with 10% phenol in
trifluoroacetic acid (TFA) for 3 h gave the C-terminally amidated peptides. The
crude peptide products were precipitated in diethyl ether and lyophilized from
10% acetic acid. Purification was carried out by preparative high-performance
liquid chromatography (HPLC) using an LC-10AD system (Shimadzu, Kyoto,
Japan) operating at 220 nm, yielding a purity better than 95% as determined by
analytical reversed-phase HPLC on an LC-10AD instrument (Jasco, Germany)
using an A300 Polyencap column (250×20 mm; Bischoff Analysentechnik und
-geräte, Leonberg, Germany) and a flow gradient of 10 mL/min with 40–95% B
(80% acetonitrile, 20% H2O, 0.1% TFA) in A (0.1% TFA in H2O for 70 min).
The compounds were further characterized by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF) on a Voyager-DE
STR (Applied Biosystems, Foster City, USA).
2.3. Liposome preparation
Small and large unilamellar vesicles (SUVs and LUVs, respectively) were
prepared as described elsewhere [29]. The dry lipid films were suspended by
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NaF or NaCl for spectroscopic or other experiments, respectively. SUVs were
made by sonification of the liposome suspension with a Labsonic L instrument (B.
Braun, Melsungen, Germany). LUVswere prepared by 35 extrusion steps through
two stacked polycarbonate filters with 100-nm pores using a MiniExtruder
(Avestin, Ontario, Canada). The vesicle size checked on a Coulter N4 Plus particle
sizer (BeckmanCoulter, Fullerton, USA)was found to be narrowly centered around
35 nm for SUVs and 100 nm for LUVs, respectively. The lipid concentration was
determined by phosphorous analysis [30]. Peptide–liposome complexes were
prepared by mixing both components at appropriate concentrations.
2.4. Circular dichroism spectroscopy
Circular dichroism (CD) measurements of peptides dissolved at 20 μM in
buffer (10mMTris, 154mMNaF, 0.1 mMEDTA, pH 7.4), in buffer/TFE (1/1 v/v)
and in 1 mM POPC SUV suspensions were carried out on a J 720 spectrometer
(Jasco, Tokyo, Japan). CD and differential scattering of the SUVs were eliminated
by subtracting the spectra of the corresponding peptide-free lipid suspensions. The
presented spectra give the mean residual ellipticity, [Θ], of one out of three
independent experiments. The peptide helicity, α, was calculated from the mean
residual ellipticity at 222 nm, Θ222, according to the equation α (%)=− (Θ222+
2340) /30300×100% [31]. The standard error in helicity was ≤5%.
2.5. Fluorescence and quenching studies
Fluorescence measurements were made on an LS 50B spectrofluorimeter
(Perkin Elmer, Rodgau-Jügesheim, Germany). Stock peptide solutions were
prepared in buffer (10 mM Tris, 154 mM NaCl, 0.1 mM EDTA, pH 7.4). POPC-
SUVs containing different amounts of the fluorescence-quenching lipid DiBr-
PSPC (0–60 mol%) were prepared as described above. Aliquots of the peptide
solutions were mixed in a 1-cm2 fluorescence cell (Hellma, Müllheim,
Germany) with either buffer or liposome suspensions to give the final peptide
concentration of 2 μMand a total lipid concentration of 2 mMwith an increasing
content of the quencher-bearing lipid. Solutions for baseline samples lacked
peptide. Peptide–vesicle interactions were recorded by measuring the
tryptophan fluorescence excited at 285 nm (slit width=5 nm) between
300 nm and 480 nm (slit width=5 nm).
The kinetic stability of peptide–liposome complexes was determined in
redistribution experiments. Aliquots of the peptide stock solutions andPOPCSUV
suspensions containing 40 mol% DiBr–PSPC were mixed in a cuvette to give a
peptide and lipid concentration of 2 μM and 2 mM, respectively, at 2500 μL
sample volume. After 30min of incubation the fluorescence intensities of the lipid-
bound peptides were determined at the wavelength of the emission maximum.
After addition of 100 μL quencher-free 40 mM SUV suspension, the final lipid
concentration was 3.8 mM. The fluorescence was registered at time intervals over
a period of another 30 min and corrected for dilution and background signals of
peptide-free suspensions. Redistribution of peptides to quencher-free vesicles was
monitored as an increase in the fluorescence intensity, whereas no intensity change
was observed with kinetically stably anchored peptides.
To determine the depth of insertion of the apoE peptides into the lipid
bilayer, fluorescence quenching experiments using nitroxide-labeled PC
(TEMPO, 5-DOX) were carried out as described elsewhere [32]. The peptides
were dissolved in ethanol. 20 μL of the 200 μM solution was given into the
lipid-containing tube to dissolve the lipid film followed by vortex mixing with
1980 μL buffer (10 mM Tris, 154 mM NaCl, 0.1 mM EDTA, pH 7.4). The final
concentrations were 200 μM lipid and 2 μM peptide, and the content of TEMPO
or 5-DOX ranged from 0 to 40 mol%. The tryptophan fluorescence excited at
285 nm was measured at 344 nm. Parallax analysis was performed as described
elsewhere [33,34]. The distance of the tryptophan chromophore from the bilayer
center, zcf, was calculated using the equation zcf =Lc1+[− ln(F1/F2)/ΠC − L212 ]/
2 L21), with Lc1 being the distance of the shallow quencher from the bilayer
center, F1 and F2 the fluorescence intensities in the presence of the shallow or
deeper quencher, respectively, and L21 the difference in depth between the
shallow and the deeper quencher. C is the mole fraction of quencher divided by
the cross-sectional area of a lipid, which is 70 Å2. The distances of the quenching
groups from the bilayer center have been reported to be 19.5 Å for TEMPO [33]
and 12.2 Å for 5-DOX [34].2.6. Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was performed on a VP instrument
(MicroCal, Northampton, USA). Experiments were made with SUVs at 25 °C.
10 μL aliquots of the suspension (lipid concentration cl =40 mM) were injected
to the peptide solution (concentration cp=20 μM) in the calorimeter cell
(V=1.3998 mL). From the sum of the heat of injections, the reaction enthalpy,
ΔH, was calculated. The heat of reaction as a function of the molar amount of
injected lipid was used to calculate binding isotherms. The evaluation of such
data sets has been explained elsewhere [35]. Binding of the cationic peptides to
SUVs can be described by a surface partition equilibrium with the condition that
the extent of peptide adsorption is linearly related to the peptide concentration at
the vesicle surface, cb: Rb=K×cb. Rb is the molar amount of peptide bound per
mole of lipid, and K is the intrinsic binding constant. cb depends on the free
peptide concentration in the bulk solution, on the peptide charge, and on the
membrane surface potential, which can be calculated with the aid of the Gouy–
Chapman theory [36]. After derivation of K from the experimental data, the
standard Gibbs free energy change, ΔG°, and the change in standard entropy,
ΔS°, were available via the relations ΔG°=−RT ln(K×55.5 M) and
ΔG°=ΔH°−TΔS°, respectively. R stands for the universal gas constant and T
for the absolute temperature. The molar concentration of water (55.5 M) corrects
for the fact that the bound peptide is given as molar ratio, whereas the aqueous
peptide concentration is given as molarity.
2.7. Dye release from liposomes
Peptide-induced bilayer permeabilization was monitored fluorimetrically by
measuring the decrease in self-quenching of vesicle-entrapped calcein as
described previously [29]. LUVs were prepared in buffered dye solution
(70 mM calcein, 10 mM Tris, 0.1 mM EDTA, pH 7.4). Calcein fluorescence
excited at 490 nm was registered at 520 nm as a function of time using an LS
50B spectrofluorimeter (Perkin Elmer, Rodgau-Jügersheim, Germany). The
peptide concentration ranged from 1 to 100 μM, the lipid concentration was
25 μM. The fluorescence intensity corresponding to 100% dequenching was
determined by addition of Triton X-100 (10% v/v in water). EC50 is the peptide
concentration inducing half-maximal dye release 5 min after peptide addition to
the liposome suspension.
2.8. Cell viability
Peptide toxicity was monitored by theMTTmethod as described before [20].
Rat brain capillary endothelial cells, RBE4 [37] were cultured in Alpha-medium/
Ham's F-10 (1/1 v/v) containing 10% (v/v) fetal bovine serum, 1% (v/v)
penicillin/ streptomycin (10000 μg/mL), 2 mM L-glutamine and 1 ng/mL
fibroblast growth factor. 25000 cells per well were seeded 48 h prior to the
experiment in a rat tail collagen-coated 96-well plate. After the medium was
removed, the cells were exposed to 200 μL increasing concentrations of apoE
peptides in growth medium for 30 min at 37 °C. After washing, addition of
180 μL fresh medium and 20 μL MTT solution in 5 mg/mL phosphate-buffered
saline (PBS) per well, and incubation the cells for 4 h at 37 °C, the medium was
replacedwith 100 μLDMSO/well. Cell viabilitywas quantified bymeasuring the
optical density at 550 nm and 650 nm as reference using a microplate reader
(Tecan Safire, Männedorf, Switzerland). Absorption determined with untreated
cells was taken as 100% cell viability.
2.9. Cellular uptake
POPC LUVs for cellular uptake studies were prepared with Dulbecco's
phosphate-buffered saline (PBS) containing Ca2+, Mg2+, and 1 mg/mL D-
glucose. Aliquots of the vesicle suspension were mixed with the P2A2 solution
to give a final lipid concentration of 1 mM and peptide concentration of 1 μM.
The complexes contained 0.1 mol% Lissamine™ rhodamine B 1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine (Rh-DPPE) in the lipid bilayer or 400 μM
fluorescein isothiocyanate-dextran WT 4000 (FITC-dextran) inside the vesicles.
Immortalized b.End3 mouse brain capillary endothelial cells [38] were cultured
in a humidified atmosphere (37 °C, 5% CO2) with Earle's minimal essential
medium supplemented with 10% fetal bovine serum, 2 mM N-acetyl-L-alanyl-L-
Table 1
Sequences of apoE peptides
Abbreviation Sequence
A2 Ac-(LRKLRKRLLR)2-NH2
A2Q Ac-(LRKLRKRLLR)2PLVEDMQRQWAGLV-NH2
A2T Ac-(LRKLRKRLLR)2AWLALALALALKALALALALKK-
NH2
MA2 myristoyl-WAG(LRKLRKRLLR)2-NH2
PA2 palmitoyl-WAG(LRKLRKRLLR)2-NH2
P2A2 palmitoyl-WK(palmitoyl)G(LRKLRKRLLR)2-NH2
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studies, cells were plated on poly-L-lysine-coated glass coverslips and maintained
under the same conditions. After 3 days, the cells were washed with PBS and
exposed to the vesicle suspension for 30 min at 37 °C followed by three washing
steps with ice-cold PBS. Fluorescence images were taken using an LSM 510
META inverted confocal laser scanningmicroscope equippedwith a PlanNeofluar
100x/1.3 Oil objective a helium/neon laser with a dichroitic HTF mirror, and an
argon laser with a DPS1 mirror (Carl Zeiss, Jena, Germany). Upon excitation at
543 nm with the He/Ne laser, rhodamine emission was registered using an LP 560
cutoff filter in front of the detector. FITCwas excited at 488 nmwith the argon laser,
and CLSM images were taken with a BP 505–530 bandpass filter. After each
experiment, membrane integrity and cell viability were ensured by trypan blue
staining.
3. Results
3.1. Peptide design and synthesis
Based on the two-domain structure of apolipoprotein E, two-
domain apoE peptides were synthesized (Table 1). The peptides
consist of the tandem dimer of residues 141–150 of apoE (A2)
shown to compete with LDL for binding to LDLr [18,20]. A2 is
characterized by a low hydrophobicity ofH=−0.73, and its ideal
helix has a high hydrophobic moment of bμN=0.4 as calculated
using the Eisenberg consensus scale for hydrophobicity [39].
The amphipathic helix, Q, corresponds to the sequence 267–280
of the lipid-associating region of apoE [40]. The hydrophobic
sequence, T, is analogous to helical peptides adopting a trans-
membrane orientation in lipid bilayers [41–43]. M and P re-
present myristoyl and palmitoyl chains, respectively, the most
common forms of protein acylation [26] and frequently used to
promote peptide association with lipid bilayers [44]. The ex-
pected localizations of A2Q, A2T, and the dipalitoylated P2A2
in lipid vesicles are schemed out in Fig. 1. All peptides containFig. 1. Different noncovalent ways of anchoring two-domain apoE peptides in
lipid bilayers.one tryptophan residue, the fluorescence of which is highly
sensitive to the environment and used to monitor peptide–lipid
interactions [45].
3.2. Circular dichroism spectroscopy
As helix formation seems to be a prerequisite for the recog-
nition of the LDL receptor by apoE peptides [46] peptide con-
formation was examined using circular dichroism spectroscopy.
The CD spectra of A2, A2Q (Fig. 2A), MA2 and PA2 dissolved
in buffer characterize highly flexible chains. The helical content
was less than 10% (Fig. 2B). A slightly enhanced helicity of
P2A2 pointed to the formation of micelles as confirmed by light
scattering and ultracentrifugation experiments [47]. The high
helix content of A2T at 20 μM concentration probably was due
to peptide association mediated by the hydrophobic transmem-
brane sequence [42]. CD spectra characterized by minima at 207
and 222 nm (Fig. 2A) and helicities greater than 75% (Fig. 2B) in
structure-inducing TFE/buffer mixtures pointed to the pro-
nounced ability of all peptides to adopt an α-helical structure. In
the presence of POPC vesicles, A2 showed only minor structural
changes, indicative of weak interactions with the lipid bilayer.Fig. 2. CD characteristics and helicities of apoE peptides. (A) CD spectra of
20 μMA2Q in buffer (solid line), in buffer/TFE (1/1 v/v) (dotted line), and in the
presence of 1 mM POPC SUVs (dashed line). [Θ] is the mean residual ellipticity.
(B) Helicity, α, of apoE peptides in buffer (black), in buffer/TFE (1/1 v/v)
(white), and in the presence of 1 mM POPC SUVs (grey). The peptide
concentration was 20 μM.
Table 2
Physicochemical properties of apoE peptides
Peptide λmax
(nm)
Fmax
(au)
λmax
(nm)
Fmax
(au)
K
(mM−1)
EC50
(μM)
cl/cp
Buffer POPC
A2 n.a. n.a. n.a. n.a. n.a. 0.03 833
A2Q 354 64 335 62 17 0.02 1250
A2T 333 110 332 127 n.d. 0.04 625
MA2 352 58 342 102 30 0.02 1250
PA2 350 61 342 110 30 0.01 2500
P2A2 344 39 342 86 NN1000 0.06 417
The fluorescence properties of 2 μMW-containing peptides were determined in
Tris buffer and in the presence of POPC-SUVs (lipid concentration cl =2 mM).
Fluorescence was excited at 280 nm (λmax, wavelength of the emission
maximum; Fmax, fluorescence intensity at λmax). The partition coefficient, K,
was derived from ITC measurements. POPC-SUVs (cl =30 mM) were titrated
into 20 μM peptide solutions in Tris buffer (n.d., not determined; n.a., not
applicable). EC50 is the half-maximal peptide concentration needed to induce
dequenching of the fluorescence of calcein entrapped in POPC-LUVs
(cl =25 μM) taken 5 min after the addition of peptide, and cl/cp gives the
corresponding lipid-to-peptide ratio.
Fig. 3. Fluorescence intensities, F, of A2Q (squares), A2T (circles), MA2 (down
triangles), PA2 (up triangles), and P2A2 (diamonds) bound to POPC vesicles in
dependence of the mole fraction, X, of the quencher-labeled lipid DiBr-PSPC.
The peptide concentration was 2 μM, the lipid concentration 2 mM. The
intensities were registered at the wavelength of the emission maximum, λmax
(Table 2).
Fig. 4. Fluorescence intensities, F, of A2Q (squares), A2T (circles), PA2 (up
triangles), and P2A2 (diamonds) bound to POPC/DiBr-PSPC (60/40 mol/mol;
lipid concentration 2 mM) measured at the wavelength of the emission
maximum, λmax, and in dependence of time after addition of POPC SUVs
(arrow). The final lipid concentration was 3.8 mM, and the peptide
concentration was 2 μM.
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liposome binding and distinctly increased helicity (Fig. 2A, B).
As shown for MA2, PA2, and P2A2, the tandem dimer A2
assumed about 40% helicity in the vesicle-bound state. Higher
helicities of A2Q and A2T might be associated with the
elongation of the peptide helix caused by the extension of the
nonpolar face of A2 with the lipid-associating sequences [22].
3.3. Fluorescence spectroscopy
Tryptophan residues fully exposed to an aqueous environ-
ment have maxima above 350 nm, whereas those that are par-
tially or completely shielded have maxima below 345 nm and at
332 nm, respectively [45]. The fluorescence maxima of A2Q,
the monoacylated MA2 and PA2 dissolved in buffer above
350 nm are indicative of an aqueous environment of their trypo-
phan residues (Table 2). The shifts in the maxima to shorter
wavelengths and the intensity increases in the presence of POPC
vesicles suggested that the aromatic residues became buried in the
hydrophobic region of the lipid bilayer. Maxima at 343 and
333 nm of buffer-dissolved P2A2 and A2T, respectively pointed
to pronounced shielding of the chromophor from the polar envi-
ronment as result of association (Table 2). Detection of their
interactionwith liposomes on the basis of environment-dependent
spectroscopic changes was not possible. Therefore, the fluores-
cence was measured in the presence of quencher-bearing lipid
vesicles. As shown in Fig. 3, all peptides showed a comparable
reduction in the emission intensity with increasing amounts of
DiBr–PSPC, indicating that also A2T and P2A2 were bound to
the lipid membrane.
To determine the kinetic stability of peptide anchoring within
the lipid bilayer, fluorescence dequenching caused by desorp-
tion form quencher-bearing liposomes was monitored. Addition
of quencher-free POPC SUVs to a A2Q-liposome suspension
containing 40 mol% DiBr–PSPC led to an immediate intensity
increase as the peptide was rapidly redistributed (Fig. 4). Over a
period of 30 min no further change was monitored. The sametransferability was observed for magainin 2 amide (data not
shown), an amphipathic helical peptide with low affinity to
neutral POPC bilayers [48]. Whereas PA2 and even A2T slowly
redistributed over a period of 30 min as shown by the slight
time-dependent increase in fluorescence intensity after SUV
addition, almost no change was observed for P2A2, suggesting
that the dipalmitoylated peptide was kinetically stably anchored
within the vesicle bilayer. The observation is in accordance with
the suggestion that a second palmitoyl anchor is needed for
stable membrane attachment of proteins [26].
To determine the position of the two peptides A2T and P2A2
in the lipid bilayer, fluorescence quenching experiments using
Table 3
Quenching of the tryptophan fluorescence by nitroxide-labeled lipids and
distance of W from the POPC bilayer center
Peptide S zcf
(Å)
TEMPO 5-DOX
A2T −2.89 −3.92 14.3
P2A2 −3.31 −4.24 14.4
S is the slope of the plot of ln (F/Fo) versus the mole fraction of lipids carrying
the nitroxide label at 19.5 Å (TEMPO) or 12.2 Å (5-DOX) from the bilayer
center. F/Fo is the ratio of the fluorescence intensity in the presence of POPC
vesicles containing the quencher to that of vesicles without the quencher. The
mole fraction of labeled lipid ranged from 0 to 0.4. The peptide concentration
was 2 μM, the lipid concentration was 400 μM. The distance of the tryptophan
residue from the bilayer center, zcf, was calculated by applying the parallax
equation [33,34].
Fig. 6. Viability, V, of rat capillary endothelial cells (RBE4) in dependence of the
concentration of A2 (open circles), A2Q (squares), A2T (circles), MA2 (down
triangles), PA2 (up triangles), and P2A2 (diamonds).
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efficient and the parallax analysis is most accurate when the
chromophore is close to the quencher [49]. The S-values
summarized in Table 3 give the slopes of the plots of ln (F/Fo)Fig. 5. Titration calorimetry of 20 μM A2Q solutions with a POPC SUV
suspension (lipid concentration 40 mM; volume of injection 10 μL) at 25 °C.
(A) The calorimetric trace gives the heat flow,Δp, versus time, t. (B) The heat of
reaction per mole of injected lipid, q, as a function of the injection number, n,
was obtained by integration of the peaks in (A). The fitted curve was calculated
by combining a surface partition equilibrium with the Gouy–Chapman theory
and corresponds to a binding constant of K=17 mM−1 (Table 2).versus the mole fraction of labelled lipid and are a measure of
the quenching efficiencies of TEMPO- and 5-DOX-labeled
lipids on POPC-bound peptides. The calculated distance from
the bilayer centre, zcf, was 14.4 Å for tryptophan located at the
acylated N-terminus of P2A2 and 14.3 Å for the chromophore
positioned between the A2 sequence and the transmembrane
helix in A2T. Thus, both chromophores are located next to the
head group-acyl chain interface and the adjacent A2 domains
are likely exposed to the surface.
3.4. Isothermal titration calorimetry
Peptide binding was quantified by isothermal titration calo-
rimetric studies. Results from a typical experiment are shown in
Fig. 5. The exothermic heats of reaction decreased with con-
secutive POPC SUV injections into the A2Q solution because
less and less peptide was available for binding (Fig. 5A).
Towards the end of the experiment, the heats of reaction given
in Fig. 5B approached the constant heat of dilution, indicating
that almost all peptide was bound to the vesicles. For A2Q, the
molar transfer enthalpy from the aqueous solution into the lipid
bilayer was determined to be ΔH=−21.4 kcal mol−1, and the
hydrophobic partition coefficient was K=17 mM−1. The stan-
dard Gibbs free energy change upon partitioning was calculated
asΔG°=−8.2 kcal mol−1, and the standard entropy change was
ΔS°=−44.5 cal mol−1 K−1. Thus, binding of the amphipathic
peptide to POPC vesicles is an enthalpy-driven reaction opposed
by entropy. Hydrophobic binding constants derived for the
investigated two-domain peptides are summarized in Table 2.
The lipid affinity of the highly positively charged unmodified
A2 could not be determined as the ITC signals did not exceed
typical heats of dilution. The partitioning of P2A2 between the
aqueous and the bilayer phase could not be quantified because of
the low monomeric solubility, but other titration calorimetric
studies imply that the partition constant is much higher that 106
M−1 [47].
Fig. 7. CLSM pictures of mouse brain capillary endothelial cells (b.End3) incubated with Rh-DPPE-doted P2A2-liposomes (A), FITC-dextran-containing P2A2-
vesicles (B) and blank liposomes (D) for 30 min at 37 °C and exposure to Rh-DPPE-doted P2A2-liposomes for 30 min at 4 °C (C). The lipid concentration was 1 mM,
the molar peptide-to-lipid ratio was 1000 and the FITC-dextran concentration was 400 μM. Punctuated intracellular fluorescence (A, B) at 37 °C and membrane
accumulation (C) at 4 °C point to a predominant endocytotic mode of uptake of the intact liposomes. Membrane integrity and cell viability were confirmed by trypan
blue exclusion (not shown).
558 I. Sauer et al. / Biochimica et Biophysica Acta 1758 (2006) 552–5613.5. Vesicle permeabilization
Surface-active amphipathic peptides are able to perturb lipid
bilayers at sufficiently high concentrations rendering the
liposomal carrier leaky. With an EC50 value of 0.03 μM, the
bilayer-permeabilizing activity of A2 is rather high. Coupling of
lipid-associating domains had only a minor influence on the
activity, except for the P2 modification, which tended to reduce
the bilayer-disturbing effect (Table 2). Half maximal dye release
was observed at a lipid-to-P2A2 ratio of about 400. The results
suggest that permeabilization is dominated by the highly
cationic A2 helix and that the lipid-binding domains do not
provide an additional membrane-destabilizing contribution.
3.6. Cytotoxicity
The toxicity of cationic peptides is dose limiting in biological
applications. We investigated the effect of the peptides and
P2A2–liposome complexes on cells in a toxicity assay detecting
the dehydration of the MTT reagent by mitochondrial
dehydrogenase after destruction of the cell envelope. The
peptides caused toxicity of rat brain capillary endothelial cells at
micromolar peptide concentrations (Fig. 6). Cell survival was
reduced to 80% at 2 μM A2, A2Q, MA2, PA2, and P2A2. Less
toxic than the other sequences were A2T and P2A2 at higher
peptide concentrations. This decrease in cytotoxicity correlated
well with the slightly reduced bilayer permeabilization caused
by these two peptides (Table 2).3.7. Cellular uptake
Limited by the bilayer-permeabilizing and toxic activities, the
lipid-to-apoE peptide ratio of complexes used in cell biological
studies must not fall below about 400. As shown in Fig. 7, P2A2-
modified liposomes (diameter ∼100 nm) prepared at a molar
lipid-to-peptide ratio of 1000 and thus containing about 180
peptide molecules on the surface were efficiently internalized into
mouse brain capillary endothelial cells when incubated at 37 °C.
Both peptide-doted vesicles labeled with Rh-DPPE within the
lipid bilayer (Fig. 7A) or FITC-dextran dissolved in the aqueous
lumen (Fig. 7B) accumulated in distinct intracellular compart-
ments, suggesting that the intact particles are taken up by an
endocytotic process. Abolished uptake and cell surface accumu-
lation at 4 °C (Fig. 7C) supported the suggestion. Cells treated
with liposomes without P2A2 modification showed neither
intracellular nor membrane-associated fluorescence (Fig. 7D).
4. Discussion
A fundamental understanding of the interplay between the
lipid bilayer of liposomes and vector peptides is crucial for the use
of the complexes as potential carriers in drug targeting. To in-
vestigate the most efficient way of coating liposomes by ad-
sorptive coupling of an apoE-derived LDL-receptor recognition
peptide, we compared peptidesmodifiedwith an amphipathic and
transmembrane helix, a single fatty acid chain, or a dipalmitoyl
modification as vesicle anchors. The following order in the
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some complexes as pharmaceutical formulations emerged:
Binding to liposomes :
A2 bb A2Q b MA2 ¼ PA2 bb P2A2
Stability of anchorage :
A2Q bb PA2 b A2T b P2A2
Helicity :
A2 b MA2 ¼ PA2 ¼ P2A2 b A2Q b A2T
Permeabilizing activity :
A2Q ¼ A2M ¼ A2P z A2 z A2T N P2A2
Toxicity :
A2 ¼ A2Q z MA2 ¼ PA2 N P2A2 z A2T
The results suggest that the dipalmitoylated peptide, P2A2, is
most promising to prepare complexes with liposomes that are
stable on time scales relevant for biological application and to
mediate an efficient uptake into brain capillary endothelial cells.
Binding and CD spectroscopic studies demonstrating a low
affinity to neutral lipid surfaces and a high conformational flex-
ibility of A2 in aqueous solution are in agreement with previous
investigations of the sequence (129–169) [21] and (141–150)
[22]. Modifications of A2 by covalent attachment of lipid-asso-
ciating moieties served two purposes. First, they increased the
affinity of the peptides to the liposomal surface, and second, the
bound peptides folded into a helix.
As reported for many amphipathic helices of different primary
structure [48], A2Q undergoes a disordered-helix transition while
binding to the lipid bilayer. However, the low binding constant
and the immediate intervesicle transfer of the peptide upon add-
ition of liposomes to a suspension of peptide liposome complexes
suggest that the amphipathic sequence 267–280 of the lipid-
associating region of apoE [40] is not sufficient to fully anchor
the receptor binding sequence within the liposome. Thus, despite
pronounced helicity and unmodified lytic and toxic activity, A2Q
is not suitable to generate liposomal delivery systems.
Myristoyl and palmitoyl chains distinctly enhanced the lipid
affinity of A2. Unlike less cationic monoacylated peptides such
as magainin analogs [50] or proteins modified with myristoyl or
palmitoyl groups [51], which tend to form micelles in aqueous
solution in dependence of concentration, no self-association of
the two peptides was observed at 2 μM, the upper concentration
for cell experiments imposed by cytotoxicity. Systematic studies
of the effect of the acyl chain length on peptide affinity to lipid
membranes have shown that the Gibbs free energy of binding of
−8 kcal/mol provided by myristoyl [52] is insufficient to fully
anchor a peptide in the lipid bilayer. Even prolongation of the
acyl chain by two methylene units, decreasing the free energy of
binding by about −0.7 kcal/mol [53], is insufficient for
kinetically stable anchorage of the cationic A2 sequence in the
surface of liposomes composed of zwitterionic lipids.
For basic amino acid domains of proteins, electrostatic inter-
actions with anionic lipids in the membrane or a second palmitoyl
anchor have been proposed for stable membrane attachment [26].Indeed, dipalmitoyl modification of A2 pronouncedly increases
binding to lipid membranes. A thermodynamic description of the
interactions with liposomes shows that the peptide remains
anchored in the lipid bilayer above a molar lipid-to-peptide ratio
of about 80, and at lower ratios the kinetics of bilayer solu-
bilization was extremely slow [47]. The derived phase diagram of
P2A2–lipid interactions permitted mastery of liposomal, mixed
and micellar states. As shown in this study, desorption of
liposome-bound P2A2 was not detected within 30 min. This
observation is in accordance with reports for other dialkylated
apoE peptides [21] and sequences of lipidated protein fragments
[54] and suggests that binding mediated by two N-terminally
located palmitoyl chains provides complexes stable on time scales
relevant for pharmacological studies. From quenching studies one
can roughly estimate that the N-terminally located tryptophan of
P2A2 enters the acyl region of POPC bilayers up to the third
carbon. The hydrophobic gradient along the axis of an amphi-
pathic peptide determines its inclination at the hydrophobic–
hydrophilic interface and influences its mode of association
with lipids [55]. Most likely, the N-terminal position of the two
palmitoyl chains allows the A2 sequence to localize in the head-
group acyl chain interface accessible to the cell surface located
receptor.
Also, A2T forms aggregates in aqueous solution as revealed
by its fluorescence and CD-spectroscopic properties. Neverthe-
less, the peptide shows a behavior comparable to other model
transmembrane peptides [43] and partitions strongly into the
lipid bilayer. The location of the sole tryptophan residue of A2T
is 14.3 Å above the bilayer center. The same distance has been
reported for tryptophan of the transmembrane sequence
K2WL9AL9K2A [56].
Recent studies have shown that the tandem dimer of the
sequence (141–155) [57] and A2 [20] recognize the LDL
receptor. However, because of the lack in helicity, the affinity
was much reduced compared with the natural ligand LDL. Our
lipidated A2 peptides developed about 40% helicity in the lipid-
bound state. As the conformation of the receptor-binding region
in native apoE is helical [58], the induced helicity is expected to
improve peptide interactions with the receptor.
Insertion of two-domain peptides can disturb the lipid ar-
rangement of bilayers. Thus, bilayer permeabilization is distinctly
enhanced by lipidation of the antimicrobial peptide magainin [50]
and laminin-related pentapeptides [44]. At variance with such
reports, the different lipid-anchoring domains discussed here have
only minor influence on apoE peptide-induced bilayer permea-
bilization, suggesting that the high activity is determined by the
A2 sequence. Comparable activities towards neutral bilayers have
been reported for other cationic amphipathic model peptides
[29,59] and associated with their pronounced hydrophobic mo-
ment favoring insertion into the lipid bilayer. Least active are A2T
and P2A2. The disturbance of the lipid arrangement upon in-
sertion of the A2 helix into the headgroup region may be partially
compensated by the transmembrane helix or the two space-
consuming acyl chains, filling the gap in the hydrophobic bilayer
core. The detergent-like activity of P2A2 observed at molar lipid-
to-peptide ratios lower than about 80 has be analyzed in a separate
study [47].
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toxicity of the A2 peptides on capillary endothelial cells. Least
toxic seem to be the A2T, P2A2 and the liposome-bound
derivative, suggesting that peptide association reduces the cyto-
toxic effect. Comparable toxicities of A2 on capillary endothelial
cells and of the tandem dimers (141–155)2 and (141–149)2 on T
lymphocytes [60] point to a cell-type-unspecific effect. Probably,
the toxic effect is mediated by strong electrostatic interactions
between the highly cationic apoE sequences with negatively
charged cell surface heparan sulfate proteoglycans (HSPG) as
suggested for other apoE fragments [61].
The function of the P2A2 peptide as an efficient endocytosis
vector was confirmed in CLSM studies with mouse brain
capillary endothelial cells. The patterns of punctuated fluores-
cence after cell incubation with P2A2–liposome complexes
were comparable to those observed for P2A2 micelles [47] as
well as vesicles prepared by covalent A2 vector coupling [29].
Membrane translocation of the complex prepared by covalent
A2 linkage was LDLr-independent and determined by HSPGs
[29]. By contrast, Mims et al. showed that in spite of an increase
of non-specific binding of LDL in the presence of the diacylated
apoE peptide (129–169), a considerable greater amount of the
lipoprotein was taken up in cells with upregulated LDLr than in
cells with normal receptor expression [21]. Whether factors
such as the size of the vesicles, the liposome composition, the
surface density of the vector peptide, which all play a role in
LDLr-mediated cellular responses [12,62], favor the role of
HSPG as regulator of ligand–receptor encounters [63] and
entail the involvement of LDLr in the cellular uptake of our
P2A2 liposome complexes is presently under detailed
investigation.
In summary, the dipalmitoylated apoE peptide P2A2 seems
to be the most promising candidate for preparing targeting
and uptake-mediating liposomal carrier systems. P2A2 is
easily synthesized and characterized, and complexation with
liposomes is straightforward to analyze. The hydrophobic
modification fulfills the main purposes: anchorage of the
peptide on the liposomal surface on an application-relevant
time scale and folding into a helical receptor-binding-
competent conformation without deterioration of the vesicle
structure and release of content. Limited by the lytic activity,
the lipid-to-apoE peptide ratio of complexes used in cell
biological studies must not drop below 400, and because of
cytotoxicity, the peptide concentration is limited to 2 μM. The
peptide-mediated uptake of the colloidal system emphasizes
the potential of the cationic peptide as vector for improved
drug delivery to the brain. The results might furthermore be
used to design peptide–liposome complexes for efficient drug
delivery to other targets.
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